NASDAQ:RLMD Relmada Therapeutics (RLMD) Stock Price, News & Analysis $7.32 -0.11 (-1.48%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$7.51 +0.19 (+2.62%) As of 05/8/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Relmada Therapeutics Stock (NASDAQ:RLMD) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Relmada Therapeutics alerts:Sign Up Key Stats Today's Range$7.21▼$7.5050-Day Range$4.43▼$7.8652-Week Range$0.36▼$8.00Volume830,490 shsAverage Volume1.25 million shsMarket Capitalization$767.79 millionP/E RatioN/ADividend YieldN/APrice Target$12.00Consensus RatingModerate Buy Company Overview Relmada Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel therapies for pain and other central nervous system (CNS) disorders. The company applies a proprietary stereochemical approach to optimized drug candidates, aiming to improve safety, tolerability and efficacy profiles compared with existing treatments. Relmada’s research efforts center on modulation of NMDA receptors to address unmet needs in depression, neuropathic pain and related indications. Relmada’s lead product candidate, REL-1017 (d-methadone), is being evaluated as a potential rapid-acting and maintenance treatment for major depressive disorder, with clinical studies underway to assess its utility in both acute and long-term settings. In parallel, the company is advancing additional pipeline programs targeting neuropathic pain, including diabetic neuropathy and chemotherapy-induced peripheral neuropathy. Relmada collaborates with academic centers and contract research organizations to conduct multi-center trials across North America and Europe. Headquartered in New York, Relmada Therapeutics was incorporated in Delaware and maintains its research operations in the United States. The company is led by a management team with extensive experience in biopharmaceutical development, regulatory strategy and commercial planning. Relmada’s common stock is listed on the NASDAQ under the symbol RLMD.AI Generated. May Contain Errors. Read More Relmada Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks38th Percentile Overall ScoreRLMD MarketRank™: Relmada Therapeutics scored higher than 38% of companies evaluated by MarketBeat, and ranked 649th out of 857 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingModerate Buy Consensus RatingRelmada Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 1 strong buy rating, 4 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialRelmada Therapeutics has a consensus price target of $12.00, representing about 63.9% upside from its current price of $7.32.Amount of Analyst CoverageRelmada Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Relmada Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Relmada Therapeutics are expected to decrease in the coming year, from ($0.72) to ($1.18) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Relmada Therapeutics is -5.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Relmada Therapeutics is -5.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRelmada Therapeutics has a P/B Ratio of 6.20. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Relmada Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.45% of the float of Relmada Therapeutics has been sold short.Short Interest Ratio / Days to CoverRelmada Therapeutics has a short interest ratio ("days to cover") of 4.78.Change versus previous monthShort interest in Relmada Therapeutics has recently increased by 2.50%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRelmada Therapeutics does not currently pay a dividend.Dividend GrowthRelmada Therapeutics does not have a long track record of dividend growth. News and Social Media2.1 / 5News Sentiment0.28 News SentimentRelmada Therapeutics has a news sentiment score of 0.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.43 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Relmada Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 3 people have searched for RLMD on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Relmada Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders14.50% of the stock of Relmada Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions45.24% of the stock of Relmada Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Relmada Therapeutics' insider trading history. Receive RLMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Relmada Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RLMD Stock News HeadlinesRelmada Therapeutics to Report First Quarter 2026 Financial Results on Tuesday, May 12, 2026May 6, 2026 | globenewswire.comRelmada Therapeutics to Present NDV-01 Abstracts at AUA2026May 5, 2026 | globenewswire.comThe cat is out the bagAlmost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered separation packages to 8,500 workers, and Oracle is reportedly eliminating up to 30,000 positions. Goldman Sachs estimates 12,400 Americans are being financially displaced every single day. Analyst Porter Stansberry says the real driver runs deeper than AI - and two Nobel Prize winners have issued the same warning. He calls it the Final Displacement, and he's releasing a full investigation with specific companies to buy and sell before the next wave hits.May 10 at 1:00 AM | Porter & Company (Ad)Mizuho Securities Remains a Buy on Relmada Therapeutics (RLMD)April 16, 2026 | theglobeandmail.comRelmada Therapeutics: 2 New Assets, 2 New 'Blockbusters'? I'd Wait And SeeMarch 30, 2026 | seekingalpha.comHere’s What Makes Mizuho Bullish on Relmada Therapeutics Inc (RLMD) StockMarch 25, 2026 | msn.comRelmada wins bullish view at Piper Sandler on cancer therapyMarch 24, 2026 | seekingalpha.comPiper Sandler initiates coverage of Relmada Therapeutics (RLMD) with overweight recommendationMarch 24, 2026 | msn.comSee More Headlines RLMD Stock Analysis - Frequently Asked Questions How have RLMD shares performed this year? Relmada Therapeutics' stock was trading at $4.83 at the start of the year. Since then, RLMD shares have increased by 51.6% and is now trading at $7.32. How were Relmada Therapeutics' earnings last quarter? Relmada Therapeutics, Inc. (NASDAQ:RLMD) issued its quarterly earnings data on Thursday, March, 19th. The company reported ($0.27) EPS for the quarter, missing analysts' consensus estimates of ($0.14) by $0.13. Read the conference call transcript. When did Relmada Therapeutics IPO? Relmada Therapeutics (RLMD) raised $0 in an initial public offering (IPO) on Thursday, October 10th 2019. The company issued 5,000,000 shares at a price of $0.00 per share. Who are Relmada Therapeutics' major shareholders? Relmada Therapeutics' top institutional shareholders include AdvisorShares Investments LLC (0.28%) and Hillsdale Investment Management Inc. (0.05%). Insiders that own company stock include Maged Shenouda, Paul Edward Kelly, Chuck Ence, Sergio Traversa, Charles J Casamento and Cedric O'gorman. View institutional ownership trends. How do I buy shares of Relmada Therapeutics? Shares of RLMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Relmada Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Relmada Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), ServiceNow (NOW), GE Aerospace (GE) and Adobe (ADBE). Company Calendar Last Earnings3/19/2026Today5/10/2026Next Earnings (Estimated)5/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (11m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 RLMD's financial health is in the Green zone, according to TradeSmith. RLMD has been in this zone for over 11 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:RLMD CIK1553643 Webwww.relmada.com Phone(786) 629-1376FaxN/AEmployees10Year Founded2004Price Target and Rating Average Price Target for Relmada Therapeutics$12.00 High Price Target$19.00 Low Price Target$8.00 Potential Upside/Downside+63.9%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($1.45) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$57.38 million Net MarginsN/A Pretax MarginN/A Return on Equity-170.83% Return on Assets-145.58% Debt Debt-to-Equity RatioN/A Current Ratio14.61 Quick Ratio14.61 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.18 per share Price / Book6.20Miscellaneous Outstanding Shares104,890,000Free Float89,679,000Market Cap$767.79 million OptionableOptionable Beta0.43 Social Links The 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:RLMD) was last updated on 5/10/2026 by MarketBeat.com Staff. From Our PartnersThe Iran War Just Broke the Gold MarketThe Iran war isn't just a geopolitical event. It's a financial one. Within hours of the strikes, oil surged...Behind the Markets | SponsoredThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...Banyan Hill Publishing | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredMassive Data Leak Exposes 512,000-Line Code That Could Change Society Forever"You won't believe what I discovered at 4 World Trade Center" When our financial media correspondent travel...Chaikin Analytics | SponsoredThe NASTY TRUTH about the SpaceX IPOIn nearly every major IPO, roughly 95% of the gains are captured before retail investors can place a trade. It...The Oxford Club | Sponsored"Computers are about to become obsolete" - George Gilder. Here’s why.George Gilder predicted the iPhone 16 years early, called Netflix a decade before it dominated streaming, and ...Eagle Publishing | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredThe trader who called 2020 and 2022 crashes issues new prediction that will impact your moneyHedge fund legend Larry Benedict - who made clients $95 million during the 2008 crisis and went 11 for 11 in 2...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Relmada Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Relmada Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
